Clinical Trials Logo

Kaposi Sarcoma clinical trials

View clinical trials related to Kaposi Sarcoma.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT04893018 Terminated - HIV Infection Clinical Trials

NT-I7 for Kaposi Sarcoma in Patients With or Without HIV

Start date: May 23, 2022
Phase: Phase 1
Study type: Interventional

This phase I trial studies the best dose and effects of NT-I7 in treating Kaposi sarcoma in patients with or without HIV. NT-I7 works by using a patient's immune system to fight cancer. It is made in a laboratory and is used to boost, direct, or restore the body's natural defenses against cancer. NT-I7 may work better in treating Kaposi sarcoma.

NCT ID: NCT02080416 Terminated - Gastric Cancer Clinical Trials

Nelfinavir for the Treatment of Gammaherpesvirus-Related Tumors

Start date: July 2014
Phase: Phase 0
Study type: Interventional

The goals of this study is to determine if nelfinavir can target Epstein-Barr virus (EBV) and Kaposi sarcoma-associated herpesvirus (KSHV) in patients with certain cancers.

NCT ID: NCT01412515 Terminated - Kaposi Sarcoma Clinical Trials

A Phase II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation of Oral mTOR-inhibitor Everolimus (RAD001) 10 mg Daily in Patients Suffering From Classic or Endemic Kaposi's Sarcoma

Start date: June 2008
Phase: Phase 2
Study type: Interventional

Classic Kaposi's sarcoma (CKS) is an angioproliferation associated with human herpes virus 8 (HHV8), which sometimes requires systemic treatment. Rapamycin and everolimus are mTOR inhibitors. The PI3K-AKT-mTOR pathway is activated in CKS.The aim of this study is to evaluate the rate of clinical response and tolerance to everolimus 10mg/d in CKS. Patients suffering from CKS will be enrolled in a multicenter two-stage phase II trial. At inclusion, all patients will have at least 10 lesions or more than one limb or 3% of body surface affected, in the absence of symptomatic visceral CKS. The primary endpoint is objective response to everolimus after 6 months therapy (complete or partial response per ACTG criteria). The trial is planned using Simon's minimax two-stage design to demonstrate a response rate of 50% as compared to 20% with type I error rate 2.5% and power of 90%. Accordingly, 11 patients will to be enrolled in the first stage and provided at least 3 patients responded, 15 patients will be accrued in a second stage.